Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

By sjmartinez • May 30, 2025

Medford AJ, Velimirovic M, Gefen Y, Niemierko A, Gerratana L, Davis AA, Clifton K, Keenan J, Podany E, Hensing WL, Reduzzi C, Dai CS, Kiedrowski LA, Spring LM, Ellisen LW, Doebele RC, Cristofanilli M, Getz G, Bardia A. Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes. Breast Cancer Res Treat. 2025 May 29. doi: 10.1007/s10549-025-07710-w. Epub ahead of print. PMID: 40439821.

Tags: breast cancer, circulating tumor DNA, Genomics, Hematology/Oncology, Liquid biopsy., Publications

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors

Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira[...]

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis

Britten K, Lipsyc-Sharf M, Yang EH, McCloskey S, Sedrak MS, Teshome M, LaBarbera J, Bardia A, McAndrew N. Socioeconomic disparities in long-term heart failure risk[...]